Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

Otis’ outsize exposure to the US market relative to peers gives it an attractive runway for multiyear profitable modernization and maintenance revenue growth. For the five-year period up to 2029, we ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

A new assessment of 18 Center for Medicare and Medicaid Innovation models reaffirms recent criticism of the agency’s ...

We view Schindler’s approach to shareholder distributions as broadly appropriate. The company targets a dividend payout ratio of 50% to 80% of earnings. We believe there is scope to increase ...

Here is how CNBC came to its Official MLB Team Valuations for 2025, calculated by senior sports reporter Michael Ozanian.

Mitchells & Butlers shows promise with 10.4% sales growth, reduced turnover, & gains in market share. Read more on how MBPFF ...